Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
Article in English | MEDLINE | ID: mdl-27895014

ABSTRACT

Ceftazidime-avibactam (CAZ-AVI) is a recently approved ß-lactam-ß-lactamase inhibitor combination with the potential to treat serious infections caused by carbapenem-resistant organisms. Few patients with such infections were included in the CAZ-AVI clinical trials, and clinical experience is lacking. We present a case series of patients with infections caused by carbapenem-resistant Enterobacteriaceae (CRE) or Pseudomonas aeruginosa (CRPa) who were treated with CAZ-AVI salvage therapy on a compassionate-use basis. Physicians who had prescribed CAZ-AVI completed a case report form. We used descriptive statistics to summarize patient characteristics and treatment outcomes. We used the Wilcoxon rank sum test and Fisher's exact test to compare patients by treatment outcome. The sample included 36 patients infected with CRE and two with CRPa. The most common infections were intra-abdominal. Physicians categorized 60.5% of patients as having life-threatening infections. All but two patients received other antibiotics before CAZ-AVI, for a median of 13 days. The median duration of CAZ-AVI treatment was 16 days. Twenty-five patients (65.8%) concurrently received other antibiotics to which their pathogen was nonresistant in vitro Twenty-eight patients (73.7%, 95% confidence interval [CI], 56.9 to 86.6%) experienced clinical and/or microbiological cure. Five patients (20.8%) with documented microbiological cure died, whereas 10 patients (71.4%) with no documented microbiological cure died (P = 0.01). In three-quarters of cases, CAZ-AVI (alone or combined with other antibiotics) cured infections caused by carbapenem-resistant organisms, 95% of which had failed previous therapy. Microbiological cure was associated with improved survival. CAZ-AVI shows promising clinical results for infections for which treatment options are limited.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Azabicyclo Compounds/therapeutic use , Carbapenems/therapeutic use , Ceftazidime/therapeutic use , Aged , Anti-Bacterial Agents/pharmacology , Azabicyclo Compounds/pharmacology , Carbapenems/pharmacology , Ceftazidime/pharmacology , Drug Combinations , Enterobacteriaceae/drug effects , Enterobacteriaceae/pathogenicity , Female , Humans , Klebsiella oxytoca/drug effects , Klebsiella oxytoca/pathogenicity , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/pathogenicity , Male , Microbial Sensitivity Tests , Middle Aged , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/pathogenicity , Salvage Therapy
3.
Diagn Microbiol Infect Dis ; 86(1): 58-60, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27352730

ABSTRACT

Molecular epidemiology allows us to know local HIV transmission and to design strategies of prevention. We studied 25 HIV newly diagnosed patients with the E138A mutation since the year 2010. Most transmission networks involved young and promiscuous men who have sex with men. Recent infection was only documented in patients grouped into the smaller clusters.


Subject(s)
HIV Infections/epidemiology , HIV Infections/virology , HIV Reverse Transcriptase/genetics , HIV/classification , HIV/genetics , Mutation, Missense , Adolescent , Adult , Cluster Analysis , Female , HIV/enzymology , HIV/isolation & purification , HIV Infections/transmission , Humans , Male , Middle Aged , Molecular Epidemiology , Spain/epidemiology , Young Adult
4.
J Infect Chemother ; 22(8): 526-31, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27262751

ABSTRACT

OBJECTIVE: To determine the prevalence of nontuberculous mycobacteria (NTM) colonization and disease in cystic fibrosis (CF) patients. PATIENTS AND METHODS: All the CF patients followed-up from 2002 to 2012 with three acid-fast bacilli (AFB) cultures were included. The American Thoracic Society (ATS) criteria for NTM lung disease were applied. RESULTS: Forty-four of the 53 patients being followed-up were included. The mean time of follow-up was 7.0 years. A total of 18 patients (40.9%) were NTM positive. The NTN mean annual prevalence was 14.1%. The risk of Mycobacterium abscessus complex was higher in the group of 10-14 years-old (p < 0.001). Ten patients (22.7% of the entire cohort) met the ATS microbiological criteria. The mean annual prevalence of NTM disease was 10.4%. Seven patients (four with Mycobacterium simiae and three with M. abscessus complex) with multiple positive cultures, positive AFB smears and clinical worsening were treated. Three patients with M. simiae and none of those with M. abscessus were cured. CONCLUSIONS: Overall NTM prevalence of colonization and disease were high in our CF patients. Patients <15 years old had a higher risk of M. abscessus complex colonization. Multiple positive cultures or positive AFB smears were associated with disease.


Subject(s)
Cystic Fibrosis/microbiology , Mycobacterium Infections, Nontuberculous/epidemiology , Mycobacterium Infections, Nontuberculous/microbiology , Nontuberculous Mycobacteria/isolation & purification , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Lung/microbiology , Male , Middle Aged , Prevalence , Young Adult
6.
J Infect Chemother ; 22(9): 642-4, 2016 Sep.
Article in English | MEDLINE | ID: mdl-26964529

ABSTRACT

Trueperella bernardiae is a Gram-positive coryneform bacilli which role as human pathogen is unknown because it has been usually considered a contaminant. Furthermore its identification by biochemical test was difficult. We describe a prosthetic joint infection in a women who years ago underwent a total knee replacement with superinfection and necrosis of the patellar tendon as major complications. In the sample of synovial fluid collected grew a gram-positive bacilli which was identified by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) as T. bernardiae. The patient was treated with ciprofloxacin and currently preserves the prosthesis without signs of infection.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Arcanobacterium , Arthroplasty, Replacement, Knee/adverse effects , Ciprofloxacin/therapeutic use , Knee Prosthesis/adverse effects , Prosthesis-Related Infections/microbiology , Actinomycetales Infections/drug therapy , Aged , Arcanobacterium/isolation & purification , Female , Humans , Patellar Ligament/physiopathology , Prosthesis-Related Infections/diagnosis , Prosthesis-Related Infections/drug therapy , Superinfection/diagnosis , Superinfection/microbiology
7.
J Neurovirol ; 22(4): 529-32, 2016 08.
Article in English | MEDLINE | ID: mdl-26769041

ABSTRACT

We carried out a clinical and epidemiological study of adult patients with varicella-zoster virus central nervous system infection diagnosed by PCR in cerebrospinal fluid. Twenty-six patients were included. Twelve (46.2 %) patients were diagnosed with meningitis and fourteen (53.8 %) with meningoencephalitis. Twelve (46.2 %) had cranial nerves involvement (mainly the facial (VII) and vestibulocochlear (VIII) nerves), six (23.1 %) had cerebellar involvement, fourteen (53.8 %) had rash, and four (15.4 %) developed Ramsay Hunt syndrome. Three (11.5 %) patients had sequelae. Length of stay was significantly lower in patients diagnosed with meningitis and treatment with acyclovir was more frequent in patients diagnosed with meningoencephalitis. We believe routine detection of varicella-zoster virus, regardless of the presence of rash, is important because the patient may benefit from a different clinical management.


Subject(s)
Encephalitis, Varicella Zoster/diagnosis , Herpes Zoster Oticus/diagnosis , Herpesvirus 3, Human/pathogenicity , Meningitis, Viral/diagnosis , Acyclovir/therapeutic use , Adult , Aged , Aged, 80 and over , Antiviral Agents/therapeutic use , Central Nervous System/pathology , Central Nervous System/virology , Cerebellum/pathology , Cerebellum/virology , Cranial Nerves/pathology , Cranial Nerves/virology , Encephalitis, Varicella Zoster/cerebrospinal fluid , Encephalitis, Varicella Zoster/drug therapy , Encephalitis, Varicella Zoster/virology , Female , Herpes Zoster Oticus/cerebrospinal fluid , Herpes Zoster Oticus/drug therapy , Herpes Zoster Oticus/virology , Herpesvirus 3, Human/drug effects , Herpesvirus 3, Human/physiology , Humans , Male , Meningitis, Viral/cerebrospinal fluid , Meningitis, Viral/drug therapy , Meningitis, Viral/virology , Middle Aged , Retrospective Studies , Vestibulocochlear Nerve/pathology , Vestibulocochlear Nerve/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...